Literature DB >> 22123293

Developmental pathways in breast cancer and breast tumor-initiating cells: therapeutic implications.

Julia Izrailit1, Michael Reedijk.   

Abstract

The recognition of breast cancer as a molecularly heterogeneous disease where individual tumors display cellular hierarchy containing "primitive" stem-like tumor-initiating cells (TICs) and their derivatives, has directed efforts towards the development of personalized targeted therapies based on the characteristics of individual cancers. Targeted therapies are designed to attack processes that uniquely support cancer progression, including maintenance of TICs, invasion, metastasis, cell survival and tumor-related angiogenesis and thereby result in less collateral damage than conventional chemotherapy. Recently, it has been demonstrated that pathways such as Hedgehog (Hh), Wnt and Notch, which regulate development during embryonic life and somatic stem cells (SCs) in the adult organism, can be reactivated in malignancies and support the TIC compartment. Herein, we review the role of developmental pathways in stem cell biology and provide an up-to-date survey of pre-clinical and clinical trials of novel strategies to target them.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22123293     DOI: 10.1016/j.canlet.2011.11.028

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  22 in total

1.  Involvement of RARRES3 in the regulation of Wnt proteins acylation and signaling activities in human breast cancer cells.

Authors:  T-H Hsu; S-Y Jiang; W-L Chang; W-L Chan; R L Eckert; T M Scharadin; T-C Chang
Journal:  Cell Death Differ       Date:  2014-11-07       Impact factor: 15.828

Review 2.  Phenotypic screening in cancer drug discovery - past, present and future.

Authors:  John G Moffat; Joachim Rudolph; David Bailey
Journal:  Nat Rev Drug Discov       Date:  2014-07-18       Impact factor: 84.694

3.  Clinical applications of mouse models for breast cancer engaging HER2/neu.

Authors:  Elizabeth A Fry; Pankaj Taneja; Kazushi Inoue
Journal:  Integr Cancer Sci Ther       Date:  2016-10-28

Review 4.  Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC).

Authors:  Aiswarya Chaudhuri; Dulla Naveen Kumar; Deepa Dehari; Sanjay Singh; Pradeep Kumar; Pradeep Kumar Bolla; Dinesh Kumar; Ashish Kumar Agrawal
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-27

5.  Huaier aqueous extract inhibits stem-like characteristics of MCF7 breast cancer cells via inactivation of hedgehog pathway.

Authors:  Xiaolong Wang; Ning Zhang; Qiang Huo; Mingjuan Sun; Lun Dong; Yan Zhang; Guangwei Xu; Qifeng Yang
Journal:  Tumour Biol       Date:  2014-07-31

6.  Notch-induced transcription factors are predictive of survival and 5-fluorouracil response in colorectal cancer patients.

Authors:  P A Candy; M R Phillips; A D Redfern; S M Colley; J A Davidson; L M Stuart; B A Wood; N Zeps; P J Leedman
Journal:  Br J Cancer       Date:  2013-07-30       Impact factor: 7.640

7.  A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors.

Authors:  Lee S Rosen; Robert Wesolowski; Raffaele Baffa; Kai-Hsin Liao; Steven Y Hua; Brenda L Gibson; Steven Pirie-Shepherd; Anthony W Tolcher
Journal:  Invest New Drugs       Date:  2019-03-18       Impact factor: 3.651

8.  UV-Induced Wnt7a in the Human Skin Microenvironment Specifies the Fate of Neural Crest-Like Cells via Suppression of Notch.

Authors:  Mizuho Fukunaga-Kalabis; Denitsa M Hristova; Joshua X Wang; Ling Li; Markus V Heppt; Zhi Wei; Alexandra Gyurdieva; Marie R Webster; Masahiro Oka; Ashani T Weeraratna; Meenhard Herlyn
Journal:  J Invest Dermatol       Date:  2015-02-23       Impact factor: 8.551

9.  A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer.

Authors:  Sagar Sardesai; Mohamed Badawi; Ewa Mrozek; Evan Morgan; Mitch Phelps; Julie Stephens; Lai Wei; Mahmoud Kassem; Yonghua Ling; Maryam Lustberg; Daniel Stover; Nicole Williams; Rachel Layman; Raquel Reinbolt; Jeffrey VanDeusen; Mathew Cherian; Michael Grever; William Carson; Bhuvaneswari Ramaswamy; Robert Wesolowski
Journal:  Invest New Drugs       Date:  2020-01-17       Impact factor: 3.850

10.  Pathways to breast cancer recurrence.

Authors:  Aamir Ahmad
Journal:  ISRN Oncol       Date:  2013-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.